Patrick Michael Dillon

4.4k citations
79 papers · 3.1k · 2 hit papers · h-index 25

Impact in

  • Oncology top 2%
    • Cancer Immunotherapy and Biomarkers
    • PARP inhibition in cancer therapy
    • HER2/EGFR in Cancer Research
    • Cancer Genomics and Diagnostics
    • Breast Cancer Treatment Studies

Papers in

    • Cancer Treatment and Pharmacology 9
    • Cancer Immunotherapy and Biomarkers 8
    • Cancer Diagnosis and Treatment 5
    • Cutaneous Melanoma Detection and Management 4
    • HER2/EGFR in Cancer Research 4
    • Brain Metastases and Treatment 8

Patrick Michael Dillon

73 papers receiving 3.1k citations

Patrick Michael Dillon's Hit Papers

Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial 2022 · 517 citations
5170+2+4Years since publication100200300400500

Peers

Patrick Michael Dillon
Comparison fields: 5 of 138
  • Oncology 1.4k
  • Cancer Research 430
  • Pulmonary and Respiratory Medicine 655
  • Biological Psychiatry 51
  • Aging 39
Replace Manuel Benavides with:
Manuel Benavides Spain
Rouba Ali‐Fehmi United States
Magnus Karl Magnusson Iceland
Yue Zhao China
Cindy Neuzillet France
Frédéric FIORE France
Adam Jacob Schoenfeld United States
Paola Del Bianco Italy
Mark R. Wilkinson United States
Yangmin M. Ning United States
Patrick Michael Dillon relative to Manuel Benavides Spain Manuel Benavides's profile →
Citations per field
00.5×2×2.8×
Manuel Benavides · 1×
Citations per year

Countries citing papers authored by Patrick Michael Dillon

Since Specialization
Citations

This map shows the geographic impact of Patrick Michael Dillon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patrick Michael Dillon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patrick Michael Dillon more than expected).

Fields of papers citing papers by Patrick Michael Dillon

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Patrick Michael Dillon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patrick Michael Dillon. The network helps show where Patrick Michael Dillon may publish in the future.

Co-authors

The 25 scholars most cited alongside Patrick Michael Dillon, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Patrick Michael Dillon Line = papers co-authored together Patrick Michael Dillon links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 79 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial
Hit paper breakdown →
2022517
2
Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer
Hit paper breakdown →
2019365
3 2014228
4 2014214
5 2014142
6 2017137
7 2010131
8 2012118
9 2017110
10 201875
11 201670
12 201769
13 201759
14 201755
15 201754
16 201554
17 202046
18 201543
19 201842
20 199940

About Patrick Michael Dillon

Patrick Michael Dillon is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Radiology, Nuclear Medicine and Imaging and Dermatology, having authored 79 papers that have together received 3.1k indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (9 papers), Brain Metastases and Treatment (8 papers), Cancer Immunotherapy and Biomarkers (8 papers), Immunotherapy and Immune Responses (6 papers), Cancer Diagnosis and Treatment (5 papers), Cutaneous Melanoma Detection and Management (4 papers), Breast Cancer Treatment Studies (4 papers) and HER2/EGFR in Cancer Research (4 papers). The work is most often cited by research in Oncology (1.4k citations), Cancer Research (430 citations), Pulmonary and Respiratory Medicine (655 citations), Biological Psychiatry (51 citations) and Aging (39 citations). Patrick Michael Dillon has collaborated with scholars based in United States, Australia and Italy. Frequent co-authors include Christopher A. Moskaluk, Christopher Y. Thomas, Samhita Chakraborty, Erik A. Dill, Anne M. Mills, Timothy N. J. Bullock, Norman E. Sharpless, K. Lenhard Rudolph, Chad Torrice and Craig Lee Slingluff. Their work appears in journals such as Medical Oncology, Clinical Cancer Research, Journal for ImmunoTherapy of Cancer, JAMA Oncology and Critical Reviews in Oncology/Hematology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact